Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rinvecalinase alfa - DiaMedica Therapeutics

Next Previous
Drug Profile

Rinvecalinase alfa - DiaMedica Therapeutics

Alternative Names: DM 199; DM-99; Recombinant human tissue kallikrein-1 - DiaMedica Therapeutics; rhKLK-1 - DiaMedica

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DiaMedica
  • Developer DiaMedica; DiaMedica Therapeutics
  • Class Antidementias; Antihyperglycaemics; Antirheumatics; Insulin sensitisers; Nootropics; Recombinant proteins; Urologics; Vascular disorder therapies
  • Mechanism of Action Tissue kallikrein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Stroke
  • Phase II Preeclampsia; Renal failure; Type 2 diabetes mellitus
  • No development reported Diabetic nephropathies; Type 1 diabetes mellitus
  • Discontinued Acute kidney injury; Alzheimer's disease; Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Stroke(In volunteers) in Australia (IV)
  • 28 Jan 2026 No recent reports of development identified for phase-I development in Stroke(Treatment-experienced) in Australia (IV)
  • 19 Dec 2025 DiaMedica Therapeutics completes in-person pre-IND meeting with the US FDA for DM 199 in Preeclampsia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top